Mucosal immunity and secretory IgA
Mucosal epithelia of the human body, including the lining of the digestive, respiratory and urogenital tracts, comprises a vast surface permanently exposed to attack by exogenous pathogens. Protection of mucosal surfaces against colonization and possible invasion by pathogenic microorganisms is provided by a combination of constitutive non-specific substances such as mucus, lysozyme, lactoferrin and lactoperoxidase, and also by a specific mechanism that relies on a special class of antibodies known as sIgA [l-31. These antibodies are believed to operate by agglutinating potential invaders and facilitating their clearance by peristaltic or mucociliary movements. T h e delivery of micro-organisms and macromolecules to the mucosa-associated lymphoid tissue (MALT) is performed at the sampling site by a specialized type of highly invaginated enterocyte, the M-cell [4, 5] . M-cells ingest pathogens by phagocytosis, pass them to underlying antigen-presenting cells, which after antigen processing, activate T-cells residing in the MALT. T-helper cells, in turn, stimulate B-cells to proliferate and differentiate into IgAproducing plasma cells. Some activated T-and B-cells remain in the sampling site area and continue to produce IgA locally, whereas others spread immune protection throughout the body by entering the circulation and migrating to distant mucosal and glandular effector sites ( Figure   IgA consists of IgA dimers (I&) associated with the J-chain, which is acquired during the process of polymerization in plasma cells just before secretion [7] . In order to interact with pathogens in the luminal environment, the IgA antibodies have to be transported across the epithelium barrier by the polymeric immunoglobulin receptor (pIgR) expressed on the basolateral side of epithelial cells lining mucosal 
Mucosal passive immunization
IgA can potentially be used for passive protection or therapeutic intervention at mucosal surfaces. plants [20] and transgenic animals [21] has already proven to be a valuable source of active protein; however, not all the procedures have been shown to lead to the obtainment of homogeneous products.
Reconstitution of slgA in vitro from purified Ig& and SC
The large-scale production of sIgA is a complicated task for two main reasons: (1) the molecule is produced by two distinct types of cell; (2) the molecule is a huge complex of almost 400 kDa with crucial post-translational modifications including intra-and inter-chain disulphide bridging and extensive glycosylation. To this end, procedures have been recently established that allow the production and purification of I& from hybridoma cell lines [17] , and the expression and purification of recombinant SC (rSC) in heterologous systems [22] . Using the anti-Vibrio cholerue lipopolysaccharide (LPS)-specific hybridoma cell line, milligram amounts of I& purified from a mixture of monomers, polymers and aggregates could be recovered after a gentle method com- bining ultrafiltration, ion-exchange and sizeexclusion chromatography. The purified antibody molecule contained the heavy, light and J-chains synthesized and assembled by the parent plasma cell. When measured by ELISA, dimeric and polymeric forms bound to their cognate LPS antigen, whereas monomers did not, indicating that the different molecular forms retained their biological specificity [ 171. This finding implies that the polymeric nature of IgA is essential for increasing the avidity for antigen and thus performing its function in mucosal secretions. Using the very sensitive surface plasmon resonance assay, the binding constant of purified IgA, to the LPS antigen arranged as a monolayer in a lipid environment was found to be about 10' M-'
[17], a value similar to that reported for IgG directed against peptides [23] .
Given that I& can be obtained from hybridoma cell lines, it remained to be established whether rSC with IgA-binding capacity could be produced. Despite the discovery of SC three decades ago, little is known about the properties the molecule confers on IgA antibodies, mainly because of the impossibility of strictly comparing 'naked' IgA and the same antibody (re)associated with SC; as a matter of fact, sIgA, and not IgA, is the chief antibody at the mucosal surface [24] . Production of rSC has now been achieved in both mammalian and insect cell lines. The protein is efficiently secreted, terminally glycosylated in mammalian cells, easily purified by affinity chromatography techniques, and retains competence and specificity for binding to Ig& [22] . These characteristics, together with the capacity to become stably reassociated in vitro with Ig&, demonstrate that rSC can serve as a convenient substitute for its natural counterpart.
In vitro reconstitution of sIgA by combining rSC and I& allow the study of several aspects related to the properties of SC in the SC-IgA complex. After SC-IgA association, the two proteins recognize each other with a stoichiometry of 1: 1, as demonstrated by liquid-liquid association of the two partners and resolution on molecular sieving columns [22] . Furthermore, assembly into a covalent complex as detected in colostrum samples occurs to a degree ranging between 50 and 80%. Also, using surface plasmon resonance, it became possible for the first time to conclude that SC in sIgA molecule does not alter the affinity for the antigen [17] . In contrast, when investigating the role of SC on IgA stability in the presence of intestinal washes, we could convincingly prove that SC delays, but does not fully prevent, IgA degradation by gastric proteases ( Figure 3A) . Together, the data obtained with the recombinant products validate the in nitro approach as an alternative source of sIgA.
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Recombinant slgA as a vaccine-delivery vector
In addition to the protection of mucosal surfaces by cross-linking pathogens and promoting their clearance, sIgA in the lumen also selectively adheres to the M-cells. This was first observed in suckling rabbits as a local accumulation of milk sIgA on murine M-cells in Peyer's patches [25] . Subsequently, monoclonal mouse IgA, polyclonal rat IgA and polyclonal IgG antibodies were found to bind specifically to rabbit or mouse M-cells and to compete with each other for binding sites [26] . This series of observations raised the possibility that sIgA could promote the re-uptake of small amounts of antigens by M-cells and play a role in regulating mucosal immune response. T h e potential of sIgA to serve as a vaccinedelivery vector to target foreign epitopes into MALT was recently demonstrated [27] .
On oral administration of rabbit sIgA combined with a bacterial adjuvant to adult mice, IgA-, IgM-and IgG-producing lymphoblasts specific for SC (among other antigens present in the sIgA molecule) were detected in the Peyer's patches [27] . This suggests that SC itself can serve as a vector to target protective epitopes to the MALT and elicit an immune response. Based on molecular modelling, a surface-exposed site of domain I of rabbit SC was selected as a site of substitution for a Shigella invasin (Ipa B) epitope. The resulting antigenized SC (antSC) expressed in heterologous systems was recognized by a monoclonal antibody directed against the pathogen-specific epitope. In addition, antSC maintained I&-binding capacity, allowing in vitvo production of recombinant sIgA following the protocols previously established for the native molecule [27] .
Oral immunization with antSC-IgA combined with cholera toxin elicited both a strong systemic and a weaker mucosal (salivary) immune response against the inserted epitope ( Figure 3B) . Accordingly, the carrier SC molecule was highly immunogenic, as reported for sIgA complexes given orally with an adjuvant ( Figure 3B ). Thus SC associated with I& can serve as a delivery vehicle for oral vaccination by 
